At the news
? BEARISHIMPACT 7/10 PRESS-RELEASE filed Nov 12, 2026 at 16:10 ET
ProKidney reported Q3 2026 results with no revenue and a net loss of $51.8 million, while cash burn continues with $141.9 million in cash providing runway into mid-2027. The company also filed a $200 million at-the-market equity facility on the same day, representing potential dilution of up to 86% of current shares outstanding.
- Cash and marketable securities fell to $141.9 million from $181.6 million at Q2 2026
- Net loss before noncontrolling interest was $51.8 million for Q3 2026 vs $35.8 million in Q3 2025
- R&D expenses rose to $40.8 million from $26.8 million year-over-year
- Filed a $200 million ATM equity facility on the same day as this press release
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access